Cargando…

Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial

OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone A...

Descripción completa

Detalles Bibliográficos
Autores principales: Robins, Jared C., Khair, Andrew F., Widra, Eric A., Alper, Michael M., Nelson, Winnie W., Foster, Eric D., Sinha, Anshul, Ando, Masakazu, Heiser, Patrick W., Daftary, Gaurang S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244378/
https://www.ncbi.nlm.nih.gov/pubmed/34223253
http://dx.doi.org/10.1016/j.xfre.2020.09.010
_version_ 1783715921780539392
author Robins, Jared C.
Khair, Andrew F.
Widra, Eric A.
Alper, Michael M.
Nelson, Winnie W.
Foster, Eric D.
Sinha, Anshul
Ando, Masakazu
Heiser, Patrick W.
Daftary, Gaurang S.
author_facet Robins, Jared C.
Khair, Andrew F.
Widra, Eric A.
Alper, Michael M.
Nelson, Winnie W.
Foster, Eric D.
Sinha, Anshul
Ando, Masakazu
Heiser, Patrick W.
Daftary, Gaurang S.
author_sort Robins, Jared C.
collection PubMed
description OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial. DESIGN: Cost minimization analysis of trial results. SETTING: Thirty-one fertility centers. PATIENT(S): Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL. INTERVENTION(S): Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S): Mean cost of achieving live birth after first transfer (fresh or frozen). RESULT(S): First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH. CONCLUSION(S): Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER: NCT02554279.
format Online
Article
Text
id pubmed-8244378
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82443782021-07-02 Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial Robins, Jared C. Khair, Andrew F. Widra, Eric A. Alper, Michael M. Nelson, Winnie W. Foster, Eric D. Sinha, Anshul Ando, Masakazu Heiser, Patrick W. Daftary, Gaurang S. F S Rep Original Article OBJECTIVE: To determine the cost of achieving a live birth after first transfer using highly purified human menotropin (HP-hMG) or recombinant follicle-stimulating hormone (FSH) for controlled ovarian stimulation in predicted high-responder patients in the Menopur in Gonadotropin-releasing hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial. DESIGN: Cost minimization analysis of trial results. SETTING: Thirty-one fertility centers. PATIENT(S): Six hundred and nineteen women with serum antimüllerian hormone ≥5 ng/mL. INTERVENTION(S): Controlled ovarian stimulation with HP-hMG or recombinant FSH in a gonadotropin-releasing hormone (GnRH) antagonist assisted reproduction cycle where fresh transfer of a single blastocyst was performed unless ovarian response was excessive whereupon all embryos were cryopreserved and patients could undergo subsequent frozen blastocyst transfer within 6 months of randomization. MAIN OUTCOME MEASURE(S): Mean cost of achieving live birth after first transfer (fresh or frozen). RESULT(S): First-transfer efficacy, defined as live birth after first fresh or frozen transfer, was 54.5% for HP-hMG and 48.0% for recombinant FSH (difference 6.5%). Average cost to achieve a live birth after first transfer (fresh or frozen) was lower with HP-hMG compared with recombinant FSH. For fresh transfers, the cost was lower with HP-hMG compared with recombinant FSH. The average cost to achieve a live birth after first frozen transfer was also lower in patients treated with HP-hMG compared with recombinant FSH. CONCLUSION(S): Treatment of predicted high-responders with HP-hMG was associated with lower cost to achieve a live birth after first transfer compared with recombinant FSH. CLINICAL TRIAL REGISTRATION NUMBER: NCT02554279. Elsevier 2020-11-10 /pmc/articles/PMC8244378/ /pubmed/34223253 http://dx.doi.org/10.1016/j.xfre.2020.09.010 Text en © 2020 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Robins, Jared C.
Khair, Andrew F.
Widra, Eric A.
Alper, Michael M.
Nelson, Winnie W.
Foster, Eric D.
Sinha, Anshul
Ando, Masakazu
Heiser, Patrick W.
Daftary, Gaurang S.
Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title_full Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title_fullStr Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title_full_unstemmed Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title_short Economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the Menopur in Gonadotropin-releasing Hormone Antagonist Single Embryo Transfer–High Responder (MEGASET-HR) trial
title_sort economic evaluation of highly purified human menotropin or recombinant follicle-stimulating hormone for controlled ovarian stimulation in high-responder patients: analysis of the menopur in gonadotropin-releasing hormone antagonist single embryo transfer–high responder (megaset-hr) trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244378/
https://www.ncbi.nlm.nih.gov/pubmed/34223253
http://dx.doi.org/10.1016/j.xfre.2020.09.010
work_keys_str_mv AT robinsjaredc economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT khairandrewf economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT widraerica economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT alpermichaelm economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT nelsonwinniew economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT fosterericd economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT sinhaanshul economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT andomasakazu economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT heiserpatrickw economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial
AT daftarygaurangs economicevaluationofhighlypurifiedhumanmenotropinorrecombinantfolliclestimulatinghormoneforcontrolledovarianstimulationinhighresponderpatientsanalysisofthemenopuringonadotropinreleasinghormoneantagonistsingleembryotransferhighrespondermegasethrtrial